Pfizer Inc. (NYSE:PFE) announced today that the European Medicines
Agency’s Committee for Medicinal Products for Human Use (CHMP) has
adopted a positive opinion recommending that the indication for Prevenar
13 * (pneumococcal polysaccharide conjugate vaccine
[13-valent, adsorbed]) be expanded to include the prevention of
pneumonia caused by the 13 pneumococcal serotypes in the vaccine in
adults 18 years and older.
By Chelsey Dulaney
Priceline Group Inc. gave a disappointing outlook for its current quarter as bookings are expected to slow and foreign currency effects weigh on its performance, despite posting a better-than-expected 19.4% surge in revenue in its December-ended quarter.
By Chelsey Dulaney
Priceline Group Inc. gave a disappointing outlook for its current quarter as bookings are expected to slow and foreign currency effects weigh on its performance, despite posting better-than-expected revenue and earnings growth in its December quarter.
By Philip van Doorn, MarketWatch
The buyback will lower share count, but may also signal declining investment and growth
Priceline Chief Executive Darren Huston announced a new $3 billion share buyback program earlier Thursday with the following: "We believe that buying our stock is a wise investment of our capital and demonstrates our confidence in the long-term outlook for our business." Really?
By Tomi Kilgore, MarketWatch Hotel Tonight, HomeAway, Vayable may be of interest to Priceline
Priceline Group Inc. may have mobile in mind for its next acquisition, as it looks for further growth opportunities as a means to combat concerns over a slowing global economy.
Shares of Priceline Group Inc. (PCLN) rallied 6.9% in premarket trade Thursday, after the online travel service company's better-than-expected fourth-quarter results and new stock buyback program offset a downbeat first-quarter profit outlook.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.